NEW YORK (MedscapeWire) Nov 21 The US Food and Drug Administration (FDA) is warning consumers to immediately stop use of the product LipoKinetix, marketed as a dietary supplement by Syntrax Innovations, Inc. LipoKinetix has been implicated in a number of serious liver injuries. The FDA has received multiple reports of persons who developed acute hepatitis or liver failure while using LipoKinetix.
LipoKinetix is marketed for weight loss. It contains caffeine, yohimbine, diiodothyronine, sodium usniate, and norephedrine (also known as phenylpropanolamine [PPA], which has also been linked to increased risk of stroke in women). The injuries reported to the FDA occurred in persons between 20 and 32 years of age. No apparent cause of liver injury was identified in these reports other than use of LipoKinetix. Liver injury developed between 2 weeks and 3 months of LipoKinetix use.
Patients should consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, abdominal pain, or any change in skin color. In addition, the FDA urges healthcare professionals to review their cases of hepatitis to determine if any may be related to the use of dietary supplements in these patients.
Consumers or healthcare professionals who are aware of adverse effects after the use of this or other dietary supplement products can report the adverse event to FDA's MedWatch adverse event and product problem hot line at 1-800-FDA-1088 or via the
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!